Samantha Barton (Interviewer), Jayne V. Carey (Interviewer)
{"title":"Christophe Echeverri: from Canada to Cenix","authors":"Samantha Barton (Interviewer), Jayne V. Carey (Interviewer)","doi":"10.1016/S1741-8372(04)02453-3","DOIUrl":null,"url":null,"abstract":"<div><p>Christophe Echeverri started his research career in the field of molecular cell biology at the University of Ottawa, Canada. After completing his Masters degree in Ottawa in 1992, Christophe moved to the University of Massachusetts, MA, USA, where he studied the role of microtubule-based motors for his PhD. In 1998, a transatlantic move took Christophe to the European Molecular Biology Laboratory in Heidelberg, Germany, where his career soon took a dramatic turn. His successful post-doctorate work in applying the RNA-interference (RNAi) technique at the genome scale in <em>Caenorhabditis elegans</em> led him to co-found his own company, Cenix BioScience, in 1999. The company provides RNAi-based research services for target discovery and validation projects, worldwide. In 2003, Christophe was voted as one of the world's 100 Top Young Innovators by <em>Technology Review</em>, the Massachusetts Institute of Technology's magazine of innovation.</p></div>","PeriodicalId":100382,"journal":{"name":"Drug Discovery Today: TARGETS","volume":"3 5","pages":"Pages 179-182"},"PeriodicalIF":0.0000,"publicationDate":"2004-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1741-8372(04)02453-3","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today: TARGETS","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1741837204024533","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Christophe Echeverri started his research career in the field of molecular cell biology at the University of Ottawa, Canada. After completing his Masters degree in Ottawa in 1992, Christophe moved to the University of Massachusetts, MA, USA, where he studied the role of microtubule-based motors for his PhD. In 1998, a transatlantic move took Christophe to the European Molecular Biology Laboratory in Heidelberg, Germany, where his career soon took a dramatic turn. His successful post-doctorate work in applying the RNA-interference (RNAi) technique at the genome scale in Caenorhabditis elegans led him to co-found his own company, Cenix BioScience, in 1999. The company provides RNAi-based research services for target discovery and validation projects, worldwide. In 2003, Christophe was voted as one of the world's 100 Top Young Innovators by Technology Review, the Massachusetts Institute of Technology's magazine of innovation.